Aliases & Classifications for Ureteral Obstruction

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 12 55 44 15

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 35 593.4
MeSH 44 D014517
UMLS 72 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary : Ureteral Obstruction is related to hydronephrosis and renal fibrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Silodosin and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 hydronephrosis 32.2 TGFB1 SLC12A1 AQP2
2 renal fibrosis 32.1 TGFB1 BMP7 AGTR1
3 urinary tract obstruction 31.9 TGFB1 PTGS2 AQP2
4 end stage renal failure 31.3 TGFB1 EPO AGTR1
5 posterior urethral valves 30.5 TGFB1 AGTR2 AGTR1
6 kidney disease 30.4 TGFB1 EPO BMP7 AQP2 AGTR2 AGTR1
7 proteasome-associated autoinflammatory syndrome 1 30.1 PTGS2 NOS2 IL10
8 colitis 29.7 PTGS2 NOS2 IL10 CTNNB1
9 hypertension, essential 29.5 SLC12A1 NOS2 AGTR2 AGTR1
10 acquired immunodeficiency syndrome 29.1 TP53 IL10 EPO
11 cervical cancer 29.0 VEGFC TP53 PTGS2 NFE2L2 CTNNB1
12 bladder urothelial carcinoma 29.0 VEGFC TP53 NFE2L2 CTNNB1
13 familial adenomatous polyposis 28.7 TP53 PTGS2 CTNNB1
14 cholangiocarcinoma 28.6 VEGFC TP53 TGFB1 PTGS2 CTNNB1
15 obstructive nephropathy 10.8
16 fibrosis of extraocular muscles, congenital, 1 10.7
17 endometriosis 10.7
18 acute kidney failure 10.7
19 retroperitoneal fibrosis 10.7
20 chronic kidney disease 10.6
21 aneurysm 10.6
22 juvenile myasthenia gravis 10.6 TGFB1 IL10
23 anuria 10.6
24 pyelonephritis 10.5
25 aortic aneurysm 10.5
26 vesicoureteral reflux 1 10.5
27 acute cystitis 10.5
28 inflammatory bowel disease 25, autosomal recessive 10.4 TGFB1 IL10
29 aortic aneurysm, familial abdominal, 1 10.4
30 cystitis 10.4
31 uremia 10.4
32 familial vesicoureteral reflux 10.4 TGFB1 AGTR2
33 appendicitis 10.4
34 congenital anomalies of kidney and urinary tract 2 10.3
35 fibrosclerosis, multifocal 10.3
36 bladder cancer 10.3
37 transitional cell carcinoma 10.3
38 actinomycosis 10.3
39 chagas disease 10.3 TGFB1 NOS2 IL10
40 leukoregulin 10.3 TGFB1 PTGS2
41 ureterolithiasis 10.3
42 leptospirosis 10.3 SLC9A3 SLC12A1 IL10
43 nephrolithiasis, calcium oxalate 10.2
44 lymphoma 10.2
45 breast cancer 10.2
46 prostate cancer 10.2
47 microvascular complications of diabetes 3 10.2
48 microvascular complications of diabetes 4 10.2
49 microvascular complications of diabetes 6 10.2
50 microvascular complications of diabetes 7 10.2

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

GenomeRNAi Phenotypes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 AGTR2 BRD4 IL10 NFE2L2 NOS2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 AGTR2 BRD4 IL10 NFE2L2 NOS2 TGFB1

MGI Mouse Phenotypes related to Ureteral Obstruction:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 AGTR1 AGTR2 BMP7 CTNNB1 EPO IL10
2 homeostasis/metabolism MP:0005376 10.43 AGTR1 AGTR2 AQP2 CTNNB1 EPO IL10
3 behavior/neurological MP:0005386 10.42 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 IL10
4 growth/size/body region MP:0005378 10.39 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 IL10
5 mortality/aging MP:0010768 10.36 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 EPO
6 hematopoietic system MP:0005397 10.35 AGTR1 AQP2 BMP7 CTNNB1 EPO IL10
7 cellular MP:0005384 10.33 AGTR2 CTNNB1 EPO IL10 LRP2 NFE2L2
8 digestive/alimentary MP:0005381 10.32 AGTR2 BMP7 CTNNB1 IL10 LRP2 NFE2L2
9 immune system MP:0005387 10.32 AGTR1 BMP7 CTNNB1 EPO IL10 LRP2
10 integument MP:0010771 10.27 AGTR2 AQP2 BMP7 CTNNB1 EPO IL10
11 endocrine/exocrine gland MP:0005379 10.26 AGTR2 BMP7 CTNNB1 IL10 LRP2 NOS2
12 embryo MP:0005380 10.22 BMP7 CTNNB1 EPO IL10 LRP2 NFE2L2
13 adipose tissue MP:0005375 10.21 AGTR1 AGTR2 NFE2L2 NOS2 PTGS2 SLC9A3
14 craniofacial MP:0005382 10.19 BMP7 CTNNB1 IL10 LRP2 NFE2L2 NOS2
15 renal/urinary system MP:0005367 10.17 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 LRP2
16 nervous system MP:0003631 10.15 AGTR1 AGTR2 BMP7 CTNNB1 IL10 LRP2
17 muscle MP:0005369 10.09 AGTR2 CTNNB1 EPO IL10 NOS2 NOX4
18 liver/biliary system MP:0005370 10.08 CTNNB1 EPO IL10 NFE2L2 NOS2 PTGS2
19 neoplasm MP:0002006 10.01 AGTR2 CTNNB1 IL10 NFE2L2 NOS2 PTGS2
20 reproductive system MP:0005389 10 AQP2 BMP7 CTNNB1 IL10 LRP2 NOS2
21 respiratory system MP:0005388 9.9 BMP7 CTNNB1 EPO IL10 LRP2 NFE2L2
22 skeleton MP:0005390 9.73 AGTR2 BMP7 CTNNB1 EPO IL10 LRP2
23 vision/eye MP:0005391 9.23 BMP7 CTNNB1 IL10 LRP2 NOS2 PTGS2

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Silodosin Approved Phase 4 160970-54-7
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
4
Loperamide Approved Phase 4 53179-11-6 3955
5
Opium Approved, Illicit Phase 4 8008-60-4
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
8
Belladonna Approved, Experimental Phase 4
9
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
10
BCG vaccine Investigational Phase 4
11 Tolterodine tartrate Phase 4 124937-52-6
12 Peripheral Nervous System Agents Phase 4
13 Analgesics Phase 4
14 Gastrointestinal Agents Phase 4
15 Opium Poppy Phase 4
16 Narcotics Phase 4
17 Respiratory System Agents Phase 4
18 Central Nervous System Depressants Phase 4
19 Analgesics, Opioid Phase 4
20 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
21 Butylscopolammonium Bromide Phase 4
22 Antitussive Agents Phase 4
23 Antidiarrheals Phase 4
24 Neurotransmitter Agents Phase 4
25 Adrenergic alpha-1 Receptor Antagonists Phase 4
26 Adrenergic alpha-Antagonists Phase 4
27 Adrenergic Antagonists Phase 4
28 Adrenergic Agents Phase 4
29 Immunologic Factors Phase 4
30 Alkylating Agents Phase 4
31 Adjuvants, Immunologic Phase 4
32 Nucleic Acid Synthesis Inhibitors Phase 4
33 Mitomycins Phase 4
34 Anti-Bacterial Agents Phase 4
35 Antibiotics, Antitubercular Phase 4
36 Vaccines Phase 4
37 Hemostatics Phase 3
38 Coagulants Phase 3
39 Fibrin Tissue Adhesive Phase 3
40
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
41
Tamoxifen Approved Phase 2 10540-29-1 2733526
42
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
43
Iodine Approved, Investigational Phase 2 7553-56-2 807
44
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
45
Mirabegron Approved Phase 2 223673-61-8 9865528
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47 Anti-Inflammatory Agents Phase 2
48 Estrogens Phase 2
49 Selective Estrogen Receptor Modulators Phase 2
50 glucocorticoids Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA™) in Ureteral Obstruction: Prospective, Multi-center, Open Label Study Unknown status NCT01788865 Phase 4
2 Effect of a Silicone Hydrocoated Double Loop Ureteral Stent on Symptoms and Quality of Life in Patients Undergoing F-URS for Kidney Stone; a Comparative Randomized Multicenter Clinical Study. Unknown status NCT02489656 Phase 4
3 Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
4 A 4-week, Double-blind, Randomized, Comparative and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones. Completed NCT01533389 Phase 4 Silodosin;Placebo
5 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
6 The Use of Belladonna and Opium (B&O) Suppository in the Treatment of Postoperative Stent Pain: A Randomized, Double-Blinded Control Study Completed NCT03332056 Phase 4 Belladonna and Opium
7 The Effect of Daily Versus Twice Per Day Tamsulosin on Ureteral Stent Symptoms Following Ureteroscopy for Nephrolithiasis Enrolling by invitation NCT03799120 Phase 4 Tamsulosin BID
8 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
9 Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant Completed NCT01631448 Phase 3
10 Comparison of the Efficacy of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction: A Prospective Randomized Controlled Trial Based on Exploratory Research Unknown status NCT01823575 Phase 2
11 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
12 Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
13 Assessment of Bacterial Adherence and Biofilm Formation on a Triclosan Loaded Ureteral Stent: A Phase II Study Completed NCT00250406 Phase 2
14 A Randomized Control Trial Comparing Single to Multiple Application Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
15 A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02) Recruiting NCT02744430 Phase 2 Mirabegron
16 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
17 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431
18 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
19 Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study Unknown status NCT01564303 Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
20 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
21 Laparoscopic Pyeloplasty: A Registry and Database Completed NCT00169650
22 Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent Completed NCT00166361
23 Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization Completed NCT01542593
24 Dismembered Pyeloplasty With and Without After Coming Stent in Neonatal Ureteropelvic Junction Obstruction Completed NCT02138877
25 Diagnostic Relevance of Laser Confocal Microscopy During Reno-ureteroscopy in the Context of the Screening and Follow-up of Upper Urinary Tract Tumors Completed NCT02276924
26 Lower UTI Evaluation in Women With Uterine Leiomyomata Completed NCT01123603
27 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine for the Management of Pain After Surgical Correction of Ureteropelvic Junction Stenosis Completed NCT00930046
28 Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial Recruiting NCT03709992 Trospium Chloride;Tamsulosin
29 Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population Recruiting NCT02140970 Ibuprofen;Placebo
30 Prospective Multicenter Observational Study of Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
31 Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial Recruiting NCT03482089
32 Is Routine Urinary Bladder Catheterization Necessary After Ureteroscopy and Double J Stent Placement? Recruiting NCT03713411
33 Renal Anhydramnios Fetal Therapy (RAFT) Trial Recruiting NCT03101891 Isotonic fluid
34 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Recruiting NCT02123082
35 Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA) Recruiting NCT03100409
36 Phase-I Feasibility Trial To Study The Safety Of Laser Tissue Welding For Sealing Resected Kidney Surfaces After Laparoscopic Partial Nephrectomy Active, not recruiting NCT02061605
37 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Enrolling by invitation NCT02160652
38 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Not yet recruiting NCT03266770
39 Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome Not yet recruiting NCT02812212
40 Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633
41 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction Withdrawn NCT00199472

Search NIH Clinical Center for Ureteral Obstruction

Cochrane evidence based reviews: ureteral obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

MalaCards organs/tissues related to Ureteral Obstruction:

41
Kidney, Prostate, Bone, Endothelial, Colon, Cervix, Monocytes

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 4714)
# Title Authors PMID Year
1
IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. 9 38
19536084 2009
2
Angiotensin II type 1 receptor blockade prevents decrease in adult stem-like cells in kidney after ureteral obstruction. 9 38
17692840 2007
3
Snail1 is involved in the renal epithelial-mesenchymal transition. 9 38
17692821 2007
4
Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. 9 38
16820795 2006
5
Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction. 9 38
16315065 2005
6
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. 9 38
15153562 2004
7
Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. 9 38
10894795 2000
8
A review on urinary proteins in outflow disease of the upper urinary tract. 9 38
10841920 2000
9
Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. 9 38
10594789 1999
10
Effects of experimental ureteral obstruction on platelet-derived growth factor-A and type I procollagen expression in fetal metanephric kidneys. 9 38
7819000 1994
11
SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. 9 38
1895664 1991
12
Ursolic acid inhibits epithelial-mesenchymal transition in vitro and in vivo. 38
30905239 2019
13
A modified relief of unilateral ureteral obstruction model. 38
31215300 2019
14
Deletion of discoidin domain receptor 2 attenuates renal interstitial fibrosis in a murine unilateral ureteral obstruction model. 38
31169440 2019
15
Niban protein regulates apoptosis in HK-2 cells via caspase-dependent pathway. 38
31163002 2019
16
FFNT25 ameliorates unilateral ureteral obstruction-induced renal fibrosis. 38
31140898 2019
17
Endothelial-specific deletion of Brahma-related gene 1 (BRG1) assuages unilateral ureteral obstruction induced renal injury in mice. 38
31349970 2019
18
Permanent Implantable Medical Devices in Exotic Pet Medicine. 38
31395329 2019
19
Protective effects of GPR120 agonist-programmed macrophages on renal interstitial fibrosis in unilateral ureteral obstruction (UUO) rats. 38
31261028 2019
20
Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. 38
31254585 2019
21
A rare case of metastatic sigmoid adenocarcinoma to the ureter. 38
31388493 2019
22
Astaxanthin protects against renal fibrosis through inhibiting myofibroblast activation and promoting CD8+ T cell recruitment. 38
31170498 2019
23
Activation of the prostaglandin E2 EP2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices. 38
31054202 2019
24
Petchiether A attenuates obstructive nephropathy by suppressing TGF-β/Smad3 and NF-κB signalling. 38
31211499 2019
25
Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. 38
31401712 2019
26
Interleukin‑33 promotes obstructive renal injury via macrophages. 38
31173201 2019
27
Metformin modulates immune cell infiltration into the kidney during unilateral ureteral obstruction in mice. 38
31250538 2019
28
Delayed recognition of lower urinary tract injuries following hysterectomy for benign indications: A NSQIP-based study. 38
30926265 2019
29
Effect of diabetes mellitus on the recovery of changes in renal functions and glomerular permeability following reversible 24-hour unilateral ureteral obstruction. 38
30592154 2019
30
Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats. 38
31386229 2019
31
Prediction of the mechanisms of action of shenkang in chronic kidney disease: A network pharmacology study and experimental validation. 38
31386888 2019
32
Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition. 38
31373855 2019
33
Nimbolide ameliorates unilateral ureteral obstruction-induced renal fibrosis by inhibition of TGF-β and EMT/Slug signalling. 38
31202101 2019
34
Evaluating Renal Fibrosis with R2* Histogram Analysis of the Whole Cortex in a Unilateral Ureteral Obstruction Model. 38
30111497 2019
35
Knockout of Sphingosine Kinase 1 Attenuates Renal Fibrosis in Unilateral Ureteral Obstruction Model. 38
31416077 2019
36
Silenced miR-21 inhibits renal interstitial fibrosis via targeting ERK1/2 signaling pathway in mice. 38
31389582 2019
37
Thymoquinone alleviates renal interstitial fibrosis and kidney dysfunction in rats with unilateral ureteral obstruction. 38
31215078 2019
38
Epidermal growth factor receptor mimotope alleviates renal fibrosis in murine unilateral ureteral obstruction model. 38
31152892 2019
39
Intravoxel Incoherent Motion and Arterial Spin Labeling MRI Analysis of Reversible Unilateral Ureteral Obstruction in Rats. 38
30328247 2019
40
Juvenile polymyositis associated with ureteral necrosis: a diagnostic and therapeutic dilemma-case report and review of the literature. 38
31098736 2019
41
RBP and Alb in neonatal hydronephrosis and its association with IL-12 levels in pregnant women before delivery. 38
31258686 2019
42
Treatment of fragmented and severely encrusted ureteral double-J stent forgotten for 11 years through multimodal endourological methods. 38
31413512 2019
43
Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry. 38
31358807 2019
44
Melatonin therapy protects against renal injury before and after release of bilateral ureteral obstruction in rats. 38
31100324 2019
45
Native ureteroureterostomy in renal allograft recipient surgery: A single-center 5-year experience. 38
31367074 2019
46
Anti-Apoptotic Effect of G-Protein-Coupled Receptor 40 Activation on Tumor Necrosis Factor-α-Induced Injury of Rat Proximal Tubular Cells. 38
31295865 2019
47
Tips and Tricks for Performing a Retrograde Pyelogram. 38
30959119 2019
48
The impact of ureteral deformation and external ureteral pressure on stent failure in extrinsic ureteral obstruction - An in vitro experimental study. 38
31359787 2019
49
Management of Bilateral Ureteral Obstruction After Transplantation of Pediatric En Bloc Kidneys, a Case Report and Review of Available Literature. 38
31334340 2019
50
MiR-373 exacerbates renal injury and fibrosis via NF-κB/MatrixMetalloproteinase-9 signaling by targeting Sirtuin1. 38
29723660 2019

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 VEGFC TP53 TGFB1 IL10 EPO BMP7
2
Show member pathways
12.92 VEGFC TGFB1 PTGS2 BMP7 AGTR2 AGTR1
3
Show member pathways
12.41 TP53 NOS2 IL10 CTNNB1 AGTR1
4
Show member pathways
12.39 TGFB1 NFE2L2 CTNNB1 BMP7
5
Show member pathways
12.34 TGFB1 NOX4 CTNNB1 BMP7
6
Show member pathways
12.12 TGFB1 PTGS2 NOS2 IL10
7
Show member pathways
12.1 VEGFC TP53 TGFB1 IL10 BMP7
8 12 VEGFC TP53 TGFB1 PTGS2 NOS2 NFE2L2
9 11.98 TP53 TGFB1 PTGS2 NOS2 CTNNB1
10 11.89 TP53 TGFB1 CTNNB1 BMP7
11 11.79 TGFB1 NOS2 IL10
12 11.73 TP53 PTGS2 NOS2
13 11.73 VEGFC TGFB1 NOX4 AGTR1
14 11.73 TP53 TGFB1 PTGS2 NOX4 NOS2
15 11.71 VEGFC TGFB1 PTGS2
16 11.61 TP53 TGFB1 PTGS2 NOS2 IL10
17 11.56 TP53 TGFB1 CTNNB1 BMP7
18 11.56 TGFB1 PTGS2 NOS2 IL10
19 11.54 TGFB1 NFE2L2 BMP7
20 11.44 VEGFC TP53 EPO
21 11.33 TP53 TGFB1 PTGS2 NOS2
22 11.18 TP53 PTGS2 NOS2
23 10.82 TP53 PTGS2 NOS2 EPO

GO Terms for Ureteral Obstruction

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.02 SLC9A3 SLC12A1 NOX4 LRP2 AQP2

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.96 VEGFC TGFB1 PTGS2 IL10 CTNNB1
2 cytokine-mediated signaling pathway GO:0019221 9.92 TP53 TGFB1 PTGS2 NOS2 IL10
3 response to lipopolysaccharide GO:0032496 9.91 PTGS2 NOS2 IL10 EPO
4 regulation of apoptotic process GO:0042981 9.91 TP53 TGFB1 CTNNB1 BMP7 AGTR2
5 inflammatory response GO:0006954 9.91 TGFB1 PTGS2 NOX4 NFE2L2 IL10 AGTR2
6 response to organic substance GO:0010033 9.85 TGFB1 PTGS2 IL10
7 cellular response to hypoxia GO:0071456 9.84 TP53 PTGS2 NFE2L2 BMP7
8 regulation of inflammatory response GO:0050727 9.82 PTGS2 BRD4 AGTR1
9 cellular response to drug GO:0035690 9.82 TP53 NOS2 NFE2L2
10 regulation of cell proliferation GO:0042127 9.8 TGFB1 PTGS2 NOS2 CTNNB1 AGTR1
11 positive regulation of apoptotic process GO:0043065 9.8 TP53 TGFB1 PTGS2 NOX4 CTNNB1 BMP7
12 negative regulation of cell proliferation GO:0008285 9.8 TP53 TGFB1 PTGS2 NOX4 IL10 CTNNB1
13 response to estradiol GO:0032355 9.78 TGFB1 PTGS2 CTNNB1 BMP7
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.77 VEGFC TGFB1 NFE2L2
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.77 TGFB1 CTNNB1 BMP7
16 response to hypoxia GO:0001666 9.77 VEGFC TGFB1 NOX4 NOS2 EPO
17 negative regulation of cell cycle GO:0045786 9.76 TGFB1 PTGS2 BMP7
18 epithelial to mesenchymal transition GO:0001837 9.74 TGFB1 CTNNB1 BMP7
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 IL10 BMP7
20 regulation of blood vessel diameter GO:0097746 9.67 AGTR2 AGTR1
21 morphogenesis of embryonic epithelium GO:0016331 9.67 VEGFC CTNNB1
22 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.67 TP53 TGFB1 IL10
23 cellular response to fluid shear stress GO:0071498 9.66 PTGS2 NFE2L2
24 salivary gland morphogenesis GO:0007435 9.66 TGFB1 BMP7
25 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 TGFB1
26 angiotensin-activated signaling pathway GO:0038166 9.65 AGTR2 AGTR1
27 regulation of protein import into nucleus GO:0042306 9.64 TGFB1 AGTR2
28 regulation of removal of superoxide radicals GO:2000121 9.63 NFE2L2 BMP7
29 response to vitamin D GO:0033280 9.63 TGFB1 PTGS2 BMP7
30 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.61 PTGS2 EPO
31 renin-angiotensin regulation of aldosterone production GO:0002018 9.58 AGTR2 AGTR1
32 positive regulation of reactive oxygen species metabolic process GO:2000379 9.46 TP53 NOX4 NFE2L2 AGTR1
33 aging GO:0007568 9.43 TGFB1 PTGS2 NOX4 NFE2L2 IL10 EPO
34 positive regulation of transcription, DNA-templated GO:0045893 9.28 TP53 TGFB1 NFE2L2 IL10 EPO CTNNB1
35 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 TP53 TGFB1 NFE2L2 IL10 CTNNB1 BRD4
36 negative regulation of apoptotic process GO:0043066 10.07 TP53 PTGS2 IL10 EPO CTNNB1
37 positive regulation of gene expression GO:0010628 10.03 TP53 TGFB1 NFE2L2 CTNNB1 BMP7
38 cell proliferation GO:0008283 10.02 TP53 TGFB1 LRP2 EPO CTNNB1
39 positive regulation of cell proliferation GO:0008284 10.02 VEGFC TGFB1 PTGS2 EPO CTNNB1 AGTR2

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TGFB1 IL10 EPO BMP7
2 protein binding GO:0005515 9.58 VEGFC TP53 TGFB1 SLC9A3 RPS26 PTGS2
3 growth factor activity GO:0008083 9.56 VEGFC TGFB1 IL10 BMP7
4 enzyme binding GO:0019899 9.55 TP53 TGFB1 PTGS2 CTNNB1 BRD4
5 angiotensin type II receptor activity GO:0004945 8.96 AGTR2 AGTR1

Sources for Ureteral Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....